Aurobindo Pharma stock up over 2% on USFDA nod for osteoporosis drug

Shares of Aurobindo Pharma surged over 2% on Monday after the firm got the final approval from USFDA to manufacture and market its generic Naproxen Sodium tablets used for the treatment of osteoporosis.

The stock soared 2.31% to Rs 738 on BSE. On NSE too, shares of the company climbed 2.31% to Rs 737.95.

"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Naproxen Sodium tablets USP, 220 mg," Aurobindo Pharma had said in a BSE filing on Saturday.

"The product is expected to be launched in Q1 of 2016-17," it had said.